Dear Valued Shareholders,

I am delighted to present to you our 17th Annual Report for Financial Year 2023-24. This year has been a remarkable year for all of us. We emerged more resilient and reinvigorated, and our confidence in our capabilities is reflected not only in our numbers but also in the trust that our clients have placed in us.

Through generating innovative entrepreneurial ideas, meticulous planning, and with the support of hardworking, enthusiastic, diligent, high-performance teams, working in tandem, and committed to their duties, we shall continue to fulfill our mission of expanding our production of high quality prod- ucts, to satisfy the needs of the Pharmaceutical industry.

I would like to express my sincere gratitude to my fellow colleagues on the board, my employees for their sincerity and hard work and thanks to entire Shelter team, the Stakeholders, Banks, suppliers and all associates for their valuable guidance and support during the year and assure our Stakeholders to deliver the maximum value to their stake in future through continued relentless efforts of the Shelter team.

Dear Shareholders,

It is with great pride that I present to you. From financial point we must build a stable financial base in order to contin?e doing what only shelter can do. Such a base will in turn help us contribute to so- ciety by paying the way of innovation. This year has been a remarkable one for us, marked by robust growth and strategic achievements. It is my pleasure to share our progress and outline our future ambitions with you. We have strategically evolved to expand our foot print, innovate across product lines which will deliver immense growth in upcoming years. Financial Performance and the way of Growth have been marked by robust financial performance.

Our revenue from operations reached Rs. 4002.29 Lakhs, Reflecting a year-on-year growth of 10.70%, this growth highlights the effectiveness of our strategic initiatives and strong market positioning. Our EBITDA for the year stood at Rs. 869.66 lakhs, the Profit Before Tax (PBT) was Rs. 828.26 lakhs, while our Profit After Tax (PAT) was Rs. 620.02 lakhs, translating to an Earnings Per Share (EPS) of Rs. 5.36/ Share.

These figures reflect our ability to consistently deliver value to our shareholders. We remain confident in our strategic direction and future growth prospects. We anticipate a continued growth in upcoming years with our diversified products portfolio and dedicated team to cure the world healthy. We are confident to achieve our aims with the all stakeholders.